Despite Shrinking by US$315m in the Past Week, Alkermes (NASDAQ:ALKS) Shareholders Are Still up 19% Over 5 Years
Express News | Alkami Sees Q3 Total Revenue $83.8M-$85.3M Vs $84.78M Est., Sees FY24 Total Revenue $330.5M-$333.5M Vs $331.67M Est
Why Alkermes (ALKS) Is a Top Value Stock for the Long-Term
Strong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive Outlook
Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
Press Release: Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
